SeaStar Medical Holding FDA Grants Breakthrough Device Designation to SeaStar Medicals Selective Cytopheretic Device for Cardiorenal Syndrome

  • Kevin Chung

Press/Media

Period30 Sep 2023

Media coverage

1

Media coverage

  • TitleSeaStar Medical Holding FDA Grants Breakthrough Device Designation to SeaStar Medicals Selective Cytopheretic Device for Cardiorenal Syndrome
    Media name/outletGlobal Round Up - Bullish & Bearish Signals
    Country/TerritoryUnited States
    Date30/09/23
    PersonsKevin Chung
View all 1
View less